Lemborexant

Brand names: Dayvigo · Active ingredient: Lemborexant

In short: DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance .

Forms & strengthsDAYVIGO (lemborexant) tablets are available as: 5 mg tablets: pale yellow, round, biconvex, film-coated tablets, and debossed with "5" on one side and "LЄM" on the other side. …
LabelEisai Inc.
Label updatedMar 03, 2025

What is Lemborexant used for?

DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance .

Lemborexant dosage

The recommended dosage of DAYVIGO is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability. Time to sleep onset may be delayed if taken with or soon after a meal .

Co-administration with Strong or Moderate CYP3A Inhibitors

Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors .

Co-administration with Weak CYP3A Inhibitors

The maximum recommended dosage of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors .

Co-administration with Strong or Moderate CYP3A Inducers

Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inducers .

The maximum recommended dose of DAYVIGO is 5 mg no more than once per night in patients with moderate hepatic impairment .

DAYVIGO is not recommended in patients with severe hepatic impairment .

How to take Lemborexant — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Administration Instructions

Advise patients to take DAYVIGO only when preparing for or getting into bed and only if they can stay in bed for a full night (at least 7 hours) before being active again .

Advise patients that the effect of DAYVIGO may be delayed if taken with or soon after a meal .

CNS Depressant Effects and Daytime Impairment

Advise patients that DAYVIGO can impair daytime wakefulness even when used as prescribed. The risk of daytime impairment is increased if DAYVIGO is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken. If DAYVIGO is taken in these circumstances, caution patients against driving and other activities requiring complete mental alertness. Advise patients that increased drowsiness may increase the risk of falls in some patients . …

Warnings & precautions

Do not take this medicine if: DAYVIGO is contraindicated in patients with narcolepsy.

DAYVIGO is a central nervous system (CNS) depressant that can impair daytime wakefulness even when used as prescribed. CNS depressant effects may persist in some patients for up to several days after discontinuing DAYVIGO. Prescribers should advise patients about the potential for next-day somnolence.

Driving ability was impaired in some subjects taking DAYVIGO 10 mg . The risk of daytime impairment is increased if DAYVIGO is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken . If DAYVIGO is taken in these circumstances, patients should be cautioned against driving and other activities requiring complete mental alertness.

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of DAYVIGO and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects. The use of DAYVIGO with other drugs to treat insomnia is not recommended. Patients should be advised not to consume alcohol in combination with DAYVIGO because of additive effects .

Because DAYVIGO can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls.

Sleep paralysis, an inability to move or speak for up to several minutes during sleep-wake transitions, and hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions, can occur with the use of DAYVIGO. Prescribers should explain the nature of these events to patients when prescribing DAYVIGO.

Symptoms similar to mild cataplexy can occur with DAYVIGO. …

Lemborexant side effects

The following clinically significant adverse reactions are discussed in detail in other sections of the labeling:

CNS Depressant Effects and Daytime Impairment

Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms

Complex Sleep Behaviors

Patients with Compromised Respiratory Function

Worsening of Depression/Suicidal Ideation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of DAYVIGO was evaluated in 1418 adult patients with insomnia disorder (age 18 to 88 years) from two controlled efficacy trials (Study 1 and Study 2). Study 1 was a 6-month placebo-controlled trial assessing DAYVIGO 5 or 10 mg once nightly, followed by a 6-month parallel-group extension period in which patients initially treated with DAYVIGO continued on the same dose, and patients who received placebo were re-randomized to receive DAYVIGO 5 or 10 mg once nightly. In Study 1, 434 patients were treated with DAYVIGO for one year. Study 2 was a 30-day placebo- and active-controlled trial assessing DAYVIGO 5 or 10 mg once nightly. …

Drug interactions

Table 2: Clinically Important Drug Interactions with DAYVIGO

Effect of Other Drugs on DAYVIGO

Strong, Moderate, and Weak CYP3A Inhibitors

Clinical Impact: | Concomitant use with a strong, moderate, or weak CYP3A inhibitor increases lemborexant AUC and Cmax which may increase the risk of DAYVIGO adverse reactions .

Intervention: | Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors .

The maximum recommended dose of DAYVIGO with weak CYP3A inhibitors is 5 mg .

Examples: | Strong CYP3A inhibitors: itraconazole, clarithromycinModerate CYP3A inhibitors: fluconazole, verapamilWeak CYP3A inhibitors: chlorzoxazone, ranitidine

Strong and Moderate CYP3A Inducers

Clinical Impact: | Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy .

Intervention: | Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inducers .

Examples: | Strong CYP3A inducers: rifampin, carbamazepine, St. John’s wortModerate CYP3A inducers: bosentan, efavirenz, etravirine, modafinil

Alcohol

Clinical Impact: | Concomitant use of alcohol increases lemborexant Cmax and AUC. …

About this medicine

DAYVIGO contains lemborexant, an orexin receptor antagonist. The chemical name of lemborexant is (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide. The molecular formula is C22H20F2N4O2. The molecular weight is 410.42.

The structural formula is:

Lemborexant is a white to off-white powder that is practically insoluble in water.

DAYVIGO tablets are intended for oral administration. Each film coated tablet contains 5 mg or 10 mg of lemborexant. The inactive ingredients are: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, and magnesium stearate.

In addition, the film coating contains the following inactive ingredients: hypromellose 2910, polyethylene glycol 8000, talc, titanium dioxide, and either (a) ferric oxide yellow for the 5 mg tablet; or, (b) both ferric oxide yellow and ferric oxide red for the 10 mg tablet.

How it works: The mechanism of action of lemborexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7074cb65-77b3-45d2-8e8d-da8dc0f70bfd. Read the full official label on DailyMed.

Related medicines

Tirzepatide Buspirone Venlafaxine Zolpidem Citalopram Lorazepam Temazepam Melatonin